ADP-induced platelet aggregation in vitro in patients with ischemic heart disease and peripheral thromboatherosclerosis.
ADP-induced platelet aggregation in vitro has been studied in 90 normal controls and in 30 patients with ischemic heart disease (IHD) and 22 with peripheral thromboatherosclerosis (PTA). The sensitivity to ADP was defined by the threshold concentration which produced secondary aggregation with an amplitude corresponding to not less than 80% of the transmission obtained by platelet-poor plasma. In the normal controls the threshold concentration was significantly lower in women aged 50 or more than in women under that age. The geometric means were lower in the patients than in the controls. Significantly lower threshold concentrations than in the corresponding age groups of controls were found in the following age groups of patients: Men and women greater than or equal to 50 years with IHD (p less than 0.005 and p less than 0.001, respectively), men and women under 50 with IHD (p less than 0.05). Men and women greater than or equal to 50 years with PTA (p less than 0.002 and p less than 0.01, respectively), men and women under 50 with PTA (p less than 0.005).
D000244:Adenosine Diphosphate / Q000494:pharmacology*; D000328:Adult; D000368:Aged; D001161:Arteriosclerosis / Q000097:blood*; D003327:Coronary Disease / Q000097:blood*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010974:Platelet Aggregation / Q000187:drug effects*; D013927:Thrombosis / Q000097:blood
D000244:Adenosine Diphosphate